Clinical Rheumatology

, Volume 27, Issue 4, pp 541–542 | Cite as

Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?

  • Maria G. TektonidouEmail author
  • Fotini N. Skopouli
Case Report


Tumor necrosis factor (TNF) is a proinflammatory cytokine that plays a key role in the pathogenesis of autoimmune diseases and is an important constituent of the human immune response to infection. We report the case of a 45-year-old man with psoriatic arthritis, receiving treatment with infliximab, who presented with high-grade fever, rigor, splenomegaly, acute reactive proteins, and pancytopenia. The diagnosis of visceral leishmaniasis was established. The patient reported that his dog died from Leishmania infection 5 years ago, while he was living in an area endemic for Leishmania. The use of anti-TNF biologic agent in this patient might result in new infection or reactivation of a latent infection with Leishmania, 5 years after the exposure. A detailed current and past medical history should be obtained of every patient candidate for treatment with biologic agents, and a close monitoring is needed for serious opportunistic infections, including visceral leishmaniasis.


Anti-TNF treatment Leishmaniasis Psoriatic arthritis 


  1. 1.
    Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2:602–610PubMedCrossRefGoogle Scholar
  2. 2.
    Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2006) British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368–2376PubMedCrossRefGoogle Scholar
  3. 3.
    Fabre S, Gibert C, Lechiche C, Dereure J, Jorgensen C, Sany J (2005) Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol 23:891–892PubMedGoogle Scholar
  4. 4.
    Bassetti M, Pizzorni C, Gradoni L, Del Bono V, Cutolo M, Viscoli C (2006) Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology (Oxford) 45:1446–1448CrossRefGoogle Scholar
  5. 5.
    Bagalas V, Kioumis I, Argyropoulou P, Patakas D (2007) Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol 26:1344–1345PubMedCrossRefGoogle Scholar
  6. 6.
    Jewell AP, Giles FJ (1996) Cutaneous manifestation of leishmaniasis 40 years after exposure in a patient with chronic lymphocytic leukaemia. Leuk Lymphoma 21:347–349PubMedCrossRefGoogle Scholar
  7. 7.
    Czechowicz RT, Millard TP, Smith HR, Ashton RE, Lucas SB, Hay RJ (1999) Reactivation of cutaneous leishmaniasis after surgery. Br J Dermatol 141:1113–1116PubMedCrossRefGoogle Scholar
  8. 8.
    Tumang MC, Keogh C, Moldawer LL, Helfgott DC, Teitelbaum R, Hariprashad J, Murray HW (1994) Role and effect of TNF-alpha in experimental visceral leishmaniasis. J Immunol 153:768–775PubMedGoogle Scholar
  9. 9.
    Titus RG, Sherry B, Cerami A (1989) Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med 170:2097–2104PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2007

Authors and Affiliations

  1. 1.Department of Internal MedicineEuroclinic Hospital of AthensAthensGreece

Personalised recommendations